Steatohepatitis und Steatohepatitis-getriebener Leberkrebs

Kalorienüberschuss und sitzende Lebensweise mit wenig Bewegung haben zu einer globalen Epidemie von Fettleibigkeit geführt. Es gibt zunehmend epidemiologische Hinweise darauf, dass die hepatische Konsequenz – die nicht alkoholische Fettlebererkrankung (NAFLD) – in vielen Fällen für die Entstehung des hepatozellulären Karzinoms (HCC) verantwortlich ist. Wir fassen den aktuellen Stand der Forschung auf diesem Gebiet zusammen.

• Literatur

• 1 Swinburn BA. et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet 2011; 378: 804-814
• 2 Adams LA. et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 2017; 66: 1138-1153
• 3 Younossi Z. et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018; 15: 11-20
• 4 Bhaskaran K. et al. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet 2014; 384: 755-765
• 5 European Association for the Study of the Liver et al. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1388-1402
• 6 Burt AD. et al. Diagnosis and Assessment of NAFLD: Definitions and Histopathological Classification. Semin Liver Dis 2015; 35: 207-220
• 7 Chalasani N. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline. Hepatology 2012; 55: 2005-2023
• 8 Younossi ZM. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84
• 9 Buzzetti E. et al. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016; 65: 1038-1048
• 10 Anstee QM. et al. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013; 10: 330-344
• 11 Krenkel O. et al. Therapeutic Inhibition of Inflammatory Monocyte Recruitment Reduces Steatohepatitis and Liver Fibrosis. Hepatology 2018; 67: 1270-1283
• 12 Boyle M. et al. The bidirectional impacts of alcohol consumption and the metabolic syndrome: Cofactors for progressive fatty liver disease. J Hepatol 2018; 68: 251-267
• 13 Hart CL. et al. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. Brit Med J 2010; 340: C1240 10.1136/Bmj.C1240
• 14 Singh S. et al. Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies. Clin Gastroenterol Hepatol 2015; 13: 643-654
• 15 Jemal A. et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90
• 16 Ascha MS. et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-1978
• 17 Sanyal A. et al. Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin 2010; 26: 2183-2191
• 18 Piscaglia F. et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. Hepatology 2016; 63: 827-838
• 19 Ohnishi S. et al. DNA damage in inflammation-related carcinogenesis and cancer stem cells. Oxid Med Cell Longev 2013; 2013: 387014 . doi:10.1155/2013/387014
• 20 Lin R. et al. Chronic inflammation-related DNA damage response: a driving force of gastric cardia carcinogenesis. Oncotarget 2015; 6: 2856-2864
• 21 Boege Y. et al. A Dual Role of Caspase-8 in Triggering and Sensing Proliferation-Associated DNA Damage, a Key Determinant of Liver Cancer Development. Cancer Cell 2017; 32: 342-359
• 22 Campisi J. et al. Cellular senescence: when bad things happen to good cells. Nature Rev Molec Cell Biol 2009; 8: 729-740
• 23 Fumagalli M. et al. SASPense and DDRama in cancer and ageing. Nat Cell Biol 2009; 11: 921-923
• 24 Nishida N. et al. Unique features associated with hepatic oxidative DNA damage and DNA methylation in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2016; 31: 1646-1653
• 25 Tanaka S. et al. Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. J Gastroenterol 2013; 48: 1249-1258
• 26 Pascale RM. et al. DNA-PKcs: A promising therapeutic target in human hepatocellular carcinoma?. DNA Repair 2016; 47: 12-20
• 27 Kubes P. et al. Sterile inflammation in the liver. Gastroenterology 2012; 143: 1158-1172
• 28 Davis BK. et al. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol 2011; 29: 707-735
• 29 Arrese M. et al. Innate Immunity and Inflammation in NAFLD/NASH. Dig Dis Sci 2016; 61: 1294-1303
• 30 Lanthier N. Targeting Kupffer cells in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Why and how?. World J Hepatol 2015; 7: 2184-2188
• 31 Bieghs V. et al. The innate immune response during liver inflammation and metabolic disease. Trends Immunol 2013; 34: 446-452
• 32 Shalapour S. et al. Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature 2017; 551: 340-345
• 33 EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943
• 34 Heimbach JK. et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018; 67: 358-380
• 35 Dyson J. et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol 2014; 60: 110-117
• 36 Taylor EJ. et al. Modeling the benefits and harms of surveillance for hepatocellular carcinoma: Information to support informed choices. Hepatology 2017; 66: 1546-1555
• 37 European Association for the Study of the Liver et al. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 2016; 59: 1121-1140
• 38 Bruix J. et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. J Hepatol 2017; 67: 999-1008
• 39 Mehnert JM. et al. The Challenge for Development of Valuable Immuno-oncology Biomarkers. Clin Cancer Res 2017; 23: 4970-4979
• 40 Ogle LF. et al. Imagestream detection and characterisation of circulating tumour cells – A liquid biopsy for hepatocellular carcinoma?. J Hepatol 2016; 65: 305-313
• 41 Mishra SI. et al. Exercise interventions on health-related quality of life for cancer survivors. The Cochrane database of systematic reviews. 2012: CD007566
• 42 Mishra SI. et al. Exercise interventions on health-related quality of life for people with cancer during active treatment. The Cochrane database of systematic reviews. 2012: CD008465
• 43 Gustafson MP. et al. A systems biology approach to investigating the influence of exercise and fitness on the composition of leukocytes in peripheral blood. J Immunother Cancer 2017; 5: 30
• 44 Idorn M. et al. Exercise: A new role for an old tool. Mol Cell Oncol 2016; 3: e1163005
• 45 Koelwyn GJ. et al. Exercise-dependent regulation of the tumour microenvironment. Nat Rev Cancer 2017; 17: 620-632